【个人简介】

王璐平，男，2018年获得中山大学医学博士学位，历任华南理工大学博士后/助理研究员。2023年7月加入广州医科大学药学院，主要致力于心血管药理学的研究，针对蛋白位点翻译后修饰（多聚ADP核糖基化（PAR化）、SUMO化、3-羟基丁酰化等）对心血管系统功能的调控，开展心肌肥大/心衰的发病机制和防治靶标研究；同时开展以斑马鱼模式动物病理模型进行造血系统的表观遗传修饰研究及新型化合物(药物)筛选。近五年主持国家自然科学基金一项，中国博士后科学基金一项，参与国家自然科学基金两项。

【联系方式】

chinaluping@163.com

【主持科研项目】

1. 国家自然科学基金青年项目，82104271，30万，2022-01至2024-12，在研，主持；

2. 中国博士后科学基金面上项目，2019M652878，8万，2019-09至2023-06，结题，主持；

3. 国家自然科学基金面上项目，82270121，52万，2023-01至2026-12，在研，参与；

4. 国家自然科学基金面上项目，82070163，55万，2021-01至2024-12，在研，参与。

【代表性论文】

(1) Luping Wang#; Panxia Wang^#; Suowen Xu; Zhuoming Li; Dayue Darrel Duan; Jiantao Ye; Jingyan Li; Yanqing Ding; Wenqing Zhang; Jing Lu*; Peiqing Liu*；The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy, Int J Biol Sci, 2022; 18 (2):783-799. (IF=10.75)

(2) Luping Wang; Zhuoming Li; Yinzi Tan; Qian Li; Hanwei Yang; Panxia Wang; Jing Lu*; Peiqing Liu*; PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy, Molecular and Cellular Endocrinology, 2018, 474: 137-150. (IF=4.37)

(3) Xuexiao Li^#; Luping Wang^#; Xun Qin; Xiaohui Chen; Li Li; Zhibin Huang; Wenqing Zhang*; Wei Liu*; Estrogens revert neutrophil hyperplasia by inhibiting Hif1α-cMyb pathway in zebrafish myelodysplastic syndromes models, Cell death discovery, 2022;8(1): 323. (IF=7.11)

(4) Panxia Wang; Luping Wang; Jing Lu*; Yuehuai Hu; Qianqian Wang; Zhenzhen Li; Sidong Cai; Liying Liang; Kaiteng Guo; Jiyan Xie; Junjian Wang; Rui Lan; Juan Shen*; Peiqing Liu*; SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function, Journal of Molecular and Cellular Cardiology, 2019, 133: 125-137. (IF=5.76)

(5) Qian Li; Zhuoming Li; Shuya Sun; Luping Wang; Panxia Wang; Zhen Guo; Hanwei Yang; Jiantao Ye; Jing Lu*; Peiqing Liu*; PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy, Acta Pharmacologica Sinica, 2019, 40(5): 589-598. (IF=7.17)

(6) Jingyan Li^#; Junying Huang^#; Jing Lu^#; Zhen Guo; Zhuoming Li; Hui Gao; Panxia Wang; Wenwei Luo; Sidong Cai; Yuehuai Hu; Kaiteng Guo; Luping Wang; Zhenzhen Li; Minghui Wang; Xiaolei Zhang*; Peiqing Liu*; SIRT1 represses PKC-zeta activity via regulating interplay of acetylation and phosphorylation in cardiac hypertrophy, British Journal of Pharmacology, 2019, 176(3):416-435. (IF=9.47)

(7) Hanwei Yang^#; Huiling Hong^#; Wenwei Luo; Chunmei Dai; Xinyi Chen; Luping Wang; Qian Li; Ziqing Li; Peiqing Liu*; Zhuoming Li*; mTORC2 facilitates endothelial cell senescence by suppressing Nrf2 expression via the Akt/GSK3β/C/EBPα signaling pathway, Acta Pharmacologica Sinica, 2018, 39(12): 1837-1846. (IF=7.17)